Sugi Predict

Sugi Predict / Compounds / SCHEMBL2904855

SCHEMBL2904855

SCHEMBL2904855

C[C@@H](O)C(=O)N1CCNCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 2/20 0.46
▸ CA12 O43570 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA9 Q16790 1/20 0.46
▸ CHKA P35790 1/20 0.45
▸ CHRNB2 P17787 1/20 0.43
▸ CHRNA3 P32297 1/20 0.43
▸ CHRNA4 P43681 1/20 0.43
▸ CHRNB3 Q05901 1/20 0.43
▸ CHRNA6 Q15825 1/20 0.43
▸ CHRM5 P08912 1/20 0.40
▸ CHRM3 P20309 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ SIGMAR1 Q99720 1/20 0.38
▸ HSD11B1 P28845 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5440196 1.00 CA2 (0.46) CA2CA12CA1CA9CHKA
SCHEMBL2910275 1.00 CA2 (0.46) CA2CA12CA1CA9CHKA
SCHEMBL2910273 1.00 CA2 (0.46) CA2CA12CA1CA9CHKA
SCHEMBL2904848 1.00 CA2 (0.46) CA2CA12CA1CA9CHKA
Oxalic Acid SCHEMBL15634918 0.94 CA2 (0.42) CA2CA12CA1CA9CHKA
Oxalic Acid SCHEMBL15634923 0.94 CA2 (0.42) CA2CA12CA1CA9CHKA
SCHEMBL15431986 0.92 CA2 (0.48) CA2CA12CA1CA9CHKA
Valine SCHEMBL15635145 0.84 SLC7A5 (0.48) CA2CA12CA1CA9CHKA
SCHEMBL188170 0.84 CA2 (0.48) CA2CA12CA1CA9CHKA
SCHEMBL4365547 0.84 CA2 (0.48) CA2CA12CA1CA9CHKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010496-B1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2010-08-25 — — EP claimed
US-20090054411-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2009-02-26 — — US claimed
EP-2010496-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS AstraZeneca AB (SE) 2009-01-07 — — EP claimed
WO-2007119046-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2007-10-25 — — WO claimed
US-20260124214-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2026-05-07 — — US disclosed
CN-119053600-A Heterocyclic compounds for the treatment of cancer 阿提奥斯医药有限公司 2024-11-29 — — CN disclosed
WO-2023067355-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-04-27 — — WO disclosed
US-9440981-B2 Pyrrolo[2, 1-F] [1,2,4]triazine derivative and use thereof for treating tumors PHARMABLOCK (NANJING) R&D CO. LTD (CN) 2016-09-13 — — US disclosed
US-20160115166-A1 PYRROLO[2, 1-F] [1,2,4]TRIAZINE DERIVATIVE AND USE THEREOF FOR TREATING TUMORS PHARMABLOCK (NANJING) R&D CO. LTD. (CN) 2016-04-28 — — US disclosed
EP-2857402-A1 PYRROLE [2, 1-F][1, 2, 4]TRIAZINE DERIVATIVE AND ANTITUMOR EFFECT THEREOF Pharmablock (Nanjing) R&D Co., Ltd. (CN) 2015-04-08 — — EP disclosed
CN-102675323-B Pyrrole-[2, 1-f] [1, 2 and 4] triazine derivative and antitumor effect thereof PHARMABLOCK NANJING R & D CO LTD 2014-04-09 — — CN disclosed
WO-2012052730-A1 USE OF PI3K INIBITORS FOR THE TREATMENT OF OBESITY, STEATOSIS AND AGEING CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2012-04-26 — — WO disclosed
WO-2012052745-A1 COMBINATIONS OF PI3K INHIBITORS WITH A SECOND ANTI -TUMOR AGENT CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2012-04-26 — — WO disclosed
WO-2010119264-A1 IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCÓLOGICAS (CNIO) (ES) 2010-10-21 — — WO disclosed
EP-2010496-B1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2010-08-25 — — EP disclosed
US-20090054411-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2009-02-26 — — US disclosed
EP-2010496-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS AstraZeneca AB (SE) 2009-01-07 — — EP disclosed
WO-2007119046-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2007-10-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124214-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CBR1, NR3C1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 CA2 1166/4885CA12 676/4885CA1 973/4885
US-20160115166-A1 PYRROLO[2, 1-F] [1,2,4]TRIAZINE DERIVATIVE AND USE THEREOF FOR TREATING TUMORS GLS2, GTF2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 CA2 3386/4885CA12 2008/4885CA1 1626/4885
US-20090054411-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS CSF1R, CSF3R, FLT3 CA2 1554/4885CA12 2933/4885CA1 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.